Growth
For In Vivo's 17th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
CMO Tahamtan Ahmadi explained Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.
Ten $1bn+ alliances were penned in January, and two exceeded $2bn.
During Q4, biopharmas brought in an aggregate $16.8bn in financing and device company fundraising totaled $2.3bn; while in vitro diagnostic firms and research tools players raised $294m.
Now that one of the most controversial pharma M&As of 2024 has closed, did overtures to concerned customers and extended prenotification discussions help Novo and Catalent seal the deal?
The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.
It’s time for In Vivo's 17th annual Deals of the Year contest. We've chosen 12 nominees across three categories – Top M&A, Top Alliance, and Top Financing – and now it’s your turn to pick the winners.
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
As the pharmaceutical sector evolves, the landscape of sales-driving indications is set for transformation by 2030. This article explores the therapeutic areas poised for substantial growth and examines how leading companies are strategically positioning themselves to capitalize on these emerging opportunities.
The ability of artificial intelligence tools to distinguish correlation from causation could prove to be a boon to the industry.
In 2023, China emerged as the second largest exporter in the global biopharmaceutical pipeline. While innovation, international expansion, and commercialization remain pivotal, the industry's growth has increasingly relied on industrial efforts due to less active capital markets.
Six $1bn+ alliances were penned in November, and three exceeded $2bn.
Data provided by Biomedtracker show that data-driven methodologies within R&D are propelling life sciences to unprecedented advancements. It is making drug development faster, more efficient and more personalized.
Circular RNA has several advantages, but the field is young. Scandinavian startup Circio Holdings believes its version of the technology will prove the most robust.
While medtechs still find the investment environment difficult, good companies will continue to get funded. So says Taylor Wessing partner Ross McNaughton, adding that UK life sciences innovators should in the longer-term benefit from more funds going into VC and PE under The Mansion House Compact.
AI and machine learning can help companies push failures further up to avoid costly late-stage disappointments.
Attrition among biotechs and VCs holding onto their reserve capital for existing investments may have reduced the capital available for new life sciences funding, but UK-based LifeArc Ventures believes its recent activity is indicative of a general upswing.
The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.